Economic value of ribociclib in early breast cancer in the United States.
Saved in:
| Title: | Economic value of ribociclib in early breast cancer in the United States. |
|---|---|
| Authors: | Brufsky A; Department of Medicine, Hematology/Oncology, University of Pittsburgh School of Medicine, PA., Tolaney SM; Dana-Farber Cancer Institute, Boston, MA., Gadi VK; University of Illinois Cancer Center, Chicago., Chai X; Analysis Group, Inc., Boston, MA., Yang F; Analysis Group, Inc., Boston, MA., Chen W; Analysis Group, Inc., Boston, MA., Ma W; Analysis Group, Inc., Boston, MA., Zhou ZY; Analysis Group, Inc., Boston, MA., Ganapathy V; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Patel A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Alexander E; Novartis Ireland Ltd., Dublin, Ireland., Bollu V; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Garrison LP Jr; The CHOICE Institute, Department of Pharmacy, University of Washington, Seattle., Sparano JA; Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY. |
| Source: | Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2026 Aug; Vol. 32 (8), pp. 911-922. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
